Abbott Labs (ABT $52.01 +0.48) reported interim results from Phase III
open-label study of investigational treatment for advanced Parkinson's disease;
patients reported improvement in motor symptoms.
The company reported interim efficacy and safety results from a long-term,
54-week, Phase III open-label study of its investigational treatment for
advanced Parkinson's disease showed that patients treated with
levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in
"off" time and an increase in "on" time without troublesome dyskinesias.






